Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.Published in:2018By:Goss, Glenwood D.;Vokes, Everett E.;Gordon, Michael S.;Gandhi, Leena;Papadopoulos, Kyriakos P.;Rasco, Drew W.;Fischer, JuDee S.;Chu, Katharine L.;Ames, William W.;Mittapalli, Rajendar K.;Lee, Ho‐Jin;Zeng, Jiewei;Roberts‐Rapp, Lisa A.;Loberg, Lise I.;Ansell, Peter J.;Reilly, Edward B.;Ocampo, Christopher J.;Holen, Kyle D.;Tolcher, Anthony W.;Lee, Ho-JinPublication type:journal article